Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 0.76 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.63 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.41 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | GPR183 | P32249 | 1/20 | 0.41 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL590838 | 0.94 | S1PR1 (0.75) | S1PR1S1PR3TNNC1SGPL1S1PR4 | |
| SCHEMBL589819 | 0.91 | S1PR1 (0.64) | S1PR1S1PR3TNNC1SGPL1S1PR4 | |
| SCHEMBL591204 | 0.91 | S1PR1 (0.65) | S1PR1S1PR3TNNC1SGPL1S1PR4 | |
| SCHEMBL10168107 | 0.90 | S1PR1 (0.78) | S1PR1S1PR3TNNC1SGPL1S1PR4 | |
| SCHEMBL10168117 | 0.90 | S1PR1 (0.63) | S1PR1S1PR3TNNC1SGPL1S1PR4 | |
| SCHEMBL10168129 | 0.90 | S1PR1 (0.66) | S1PR1S1PR3BACE1 | |
| SCHEMBL10168104 | 0.89 | S1PR1 (0.76) | S1PR1S1PR3TNNC1SGPL1S1PR4 | |
| SCHEMBL589108 | 0.89 | S1PR1 (0.63) | S1PR1S1PR3TNNC1SGPL1S1PR4 | |
| Hydrochloric Acid SCHEMBL589947 | 0.89 | S1PR1 (0.76) | S1PR1S1PR3TNNC1SGPL1S1PR4 | |
| Hydrochloric Acid SCHEMBL590266 | 0.89 | S1PR1 (0.65) | S1PR1S1PR3BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2017257-B1 | 2-AMINOBUTANOL COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-08-06 | — | — | EP | claimed |
| US-8114902-B2 | 2-aminobutanol compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-02-14 | — | — | US | claimed |
| US-20090082311-A1 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-26 | — | — | US | claimed |
| EP-2017257-A1 | 2-AMINOBUTANOL COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-01-21 | — | — | EP | claimed |
| US-9663511-B2 | Sphingosine 1-phosphate receptor antagonists | Arroyo BioSciences, LLC (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2831072-B1 | NOVEL SPHINGOSINE 1-PHOSPHATE RECEPTOR ANTAGONISTS | ARROYO BIOSCIENCES L L C (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20150045332-A1 | Novel Sphingosine 1-Phosphate Receptor Antagonists | ARROYO BIOSCIENCES L.L.C. | 2015-02-12 | — | — | US | disclosed |
| EP-2831072-A1 | NOVEL SPHINGOSINE 1-PHOSPHATE RECEPTOR ANTAGONISTS | Swenson, Rolf E. (US) | 2015-02-04 | — | — | EP | disclosed |
| WO-2014158302-A1 | NOVEL SPHINGOSINE 1-PHOSPHATE RECEPTOR ANTAGONISTS | SWENSON ROLF ERIC (US) | 2014-10-02 | — | — | WO | disclosed |
| EP-2017257-B1 | 2-AMINOBUTANOL COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-08-06 | — | — | EP | disclosed |
| EP-2017257-B1 | 2-AMINOBUTANOL COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013148460-A1 | NOVEL SPHINGOSINE 1-PHOSPHATE RECEPTOR ANTAGONISTS | SWENSON ROLF E (US) | 2013-10-03 | — | — | WO | disclosed |
| US-8114902-B2 | 2-aminobutanol compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8114902-B2 | 2-aminobutanol compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8114902-B2 | 2-aminobutanol compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20090082311-A1 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082311-A1 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082311-A1 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-2017257-A1 | 2-AMINOBUTANOL COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-2017257-A1 | 2-AMINOBUTANOL COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045332-A1 | Novel Sphingosine 1-Phosphate Receptor Antagonists | S1PR2, S1PR1, S1PR5 | S1PR1 2/4885S1PR3 4/4885TNNC1 2198/4885 |
| US-20090082311-A1 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes | ADRB2, ADRB1, ADRB3 | S1PR1 843/4885S1PR3 583/4885TNNC1 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.